Peripherally inserted central venous catheter in Autologous Hematopoietic Stem Cell Transplantation: Feasibility and Outcome

Authors

DOI:

https://doi.org/10.46765/2675-374X.2023v4n2p197

Keywords:

Hematopoietic stem cell transplant, peripherally inserted central catheter, vascular access devices, blood stream infection, venous thrombosis

Abstract

Objectives: This study describes our experience using PICC in patients submitted to autologous stem cell transplant (ASCT) regarding the time of use, withdrawal reasons, and complications.

Methods: A retrospective cohort of 143 patients from 2017 and 2019, with a PICC inserted before the ASCT.  

Results: Regarding baseline disease, 104 (73%) of patients had multiple myeloma. The median days of use was 15 (1 – 37) per catheter. More than 80% of PICC remained in place after D+15, and 112 (78%) patients had the PICC removed at discharge. Only 13 (9%) patients had replacement of the PICC. The rates of central line associate bloodstream infection and thrombosis were 1.36 and 1.36 events per 1,000 PICC days, respectively.

Conclusions: PICCs were successfully remained until discharge, with manageable rates of complications. All procedures were executed by nurses at the bedside. We concluded that PICC is a safe and feasible alternative to CVC for ASCT.

Author Biography

Marcia Garnica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

I - DASA- Complexo Hospitalar de Niterói, Niterói, RJ, Brazil

II - Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

Downloads

Published

06/02/2023

How to Cite

Garnica, M., Valentim, M. R. ., Coelho, T. C., Cardoso Madeira, E. P., Rangel, L. da C. de O. ., Brito, A. P., & Almeida , A. R. (2023). Peripherally inserted central venous catheter in Autologous Hematopoietic Stem Cell Transplantation: Feasibility and Outcome. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 4(2), 197. https://doi.org/10.46765/2675-374X.2023v4n2p197